Dr. Graham Walmsley, MD, PhD

Dr. Walmsley serves as Managing Partner of Logos Capital, where he co-leads the firm’s private investment strategy and structured public investing efforts across all Logos funds.

Prior to Logos, Dr. Walmsley was a Principal and Portfolio Manager of the Vantage crossover fund at Versant Ventures. During his tenure at Versant, he served as a board director and played a foundational role in building and launching several biotechnology companies, including BlueRock Therapeutics (acquired by Bayer AG) and Akero Therapeutics, and led business development for Jecure Therapeutics through its acquisition by Genentech, a subsidiary of Roche.

Dr. Walmsley has authored more than 60 peer-reviewed scientific publications and holds both an MD and a PhD from Stanford University School of Medicine.

He currently serves on the boards of Akero Therapeutics (NASDAQ: AKRO) and Olema Pharmaceuticals (NASDAQ: OLMA).